Related references
Note: Only part of the references are listed.Add-on-therapy with bevacizumab in children and adolescents with poor prognosis non-CNS solid tumors
Jasmin Pansy et al.
ANTI-CANCER DRUGS (2013)
Impact of Hemochromatosis Gene Mutations on Cardiac Status in Doxorubicin-Treated Survivors of Childhood High-Risk Leukemia
Steven E. Lipshultz et al.
CANCER (2013)
An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies
Patricia Zerra et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors
Alberto Farolfi et al.
HEART (2013)
Dietary Quality, Caloric Intake, and Adiposity of Childhood Cancer Survivors and Their Siblings: An Analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study
David C. Landy et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2013)
Ethnic Group Differences in Cardiometabolic Disease Risk Factors Independent of Body Mass Index among American Youth
Sarah E. Messiah et al.
OBESITY (2013)
Dexrazoxane Use in Pediatric Patients With Acute Lymphoblastic or Myeloid Leukemia From 1999 and 2009: Analysis of a National Cohort of Patients in the Pediatric Health Information Systems Database
Dana M. Walker et al.
PEDIATRIC BLOOD & CANCER (2013)
Exercise Capacity in Long-Term Survivors of Pediatric Cancer: An Analysis From the Cardiac Risk Factors in Childhood Cancer Survivors Study
Angela M. Miller et al.
PEDIATRIC BLOOD & CANCER (2013)
Increasing Exercise in Long-Term Survivors of Pediatric Cancer and Their Siblings: Should Treatment be a Family Affair?
Rudolf Steiner
PEDIATRIC BLOOD & CANCER (2013)
Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective
Etan Orgel et al.
PEDIATRIC BLOOD & CANCER (2013)
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children
H. Visscher et al.
PEDIATRIC BLOOD & CANCER (2013)
Cranial Irradiation as an Additional Risk Factor for Anthracycline Cardiotoxicity in Childhood Cancer Survivors: An Analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study
David C. Landy et al.
PEDIATRIC CARDIOLOGY (2013)
Aggregating traditional cardiovascular disease risk factors to assess the cardiometabolic health of childhood cancer survivors: An analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study
David C. Landy et al.
AMERICAN HEART JOURNAL (2012)
Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease
Saro H. Armenian et al.
BLOOD (2012)
Protective Effect of Carvedilol on Adriamycin-Induced Left Ventricular Dysfunction in Children With Acute Lymphoblastic Leukemia
Nagla A. El-Shitany et al.
JOURNAL OF CARDIAC FAILURE (2012)
Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group
David Ebb et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cardiovascular Status of Childhood Cancer Survivors Exposed and Unexposed to Cardiotoxic Therapy
Steven E. Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes
Steven E. Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors
Helena J. van der Pal et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
Henk Visscher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes-A Report From the Children's Oncology Group
Javier G. Blanco et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
Steven E. Lipshultz et al.
PEDIATRICS (2012)
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium
Lynda M. Vrooman et al.
EUROPEAN JOURNAL OF CANCER (2011)
Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer
Barry H. Trachtenberg et al.
PEDIATRIC CARDIOLOGY (2011)
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
Lesley A. Smith et al.
BMC CANCER (2010)
Characteristics and Determinants of Adiposity in Pediatric Cancer Survivors
Tracie L. Miller et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Cardiovascular Risk Factors in Adult Survivors of Pediatric Cancer-A Report from the Childhood Cancer Survivor Study
Lillian R. Meacham et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Cardiotoxicity of epirubicin and doxorubicin: A double-blind randomized study
R. Lahtinen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience
Linzhu Zhai et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Long-term Cause-Specific Mortality Among Survivors of Childhood Cancer
Raoul C. Reulen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Cardiotoxicity After Childhood Cancer: Beginning With the End in Mind
Steven E. Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Role of Cancer Treatment in Long-Term Overall and Cardiovascular Mortality After Childhood Cancer
Markhaba Tukenova et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
Hyoung Soo Choi et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2010)
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Adriana Albini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
Steven E. Lipshultz et al.
LANCET ONCOLOGY (2010)
Antineoplastic Chemotherapy Induced QTc Prolongation
Claudia Bagnes et al.
CURRENT DRUG SAFETY (2010)
Diabetes Mellitus in Long-term Survivors of Childhood Cancer Increased Risk Associated With Radiation Therapy: A Report for the Childhood Cancer Survivor Study
Lillian R. Meacham et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Predictors of Inactive Lifestyle Among Adult Survivors of Childhood Cancer A Report From the Childhood Cancer Survivor Study
Kirsten K. Ness et al.
CANCER (2009)
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
Patrick A. Thompson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Long-Term Survivors of Childhood Cancers in the United States
Angela B. Mariotto et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Long-Term Smoking Cessation Outcomes Among Childhood Cancer Survivors in the Partnership for Health Study
Karen M. Emmons et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
Daniel A. Mulrooney et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction
Jasmine Grewal et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:Quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer
Javier G. Blanco et al.
CANCER (2008)
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane
Elly V. Barry et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cause-specific late mortality among 5-year survivors of childhood cancer: The childhood cancer survivor study
Ann C. Mertens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Bone mineral density deficits in survivors of childhood cancer: Long-term follow-up guidelines and review of the literature
Karen Wasilewski-Masker et al.
PEDIATRICS (2008)
Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: A claim without evidence
Kurt Hellmann
JOURNAL OF CLINICAL ONCOLOGY (2007)
Topoisomerase IIβ-Mediated DNA double-strand breaks:: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane
Yi Lisa Lyu et al.
CANCER RESEARCH (2007)
Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors
Melissa M. Hudson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dexrazoxane-Associated risk for secondary malignancies in pediatric Hodgkin's disease: A claim without compelling evidence
Steven E. Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Elly Barry et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Health behaviours in childhood cancer survivors: A systematic review
Sally-Ann Clarke et al.
EUROPEAN JOURNAL OF CANCER (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Availability of smoking prevention and cessation services for childhood cancer survivors
Janet S. de Moor et al.
CANCER CAUSES & CONTROL (2007)
Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma
Bassem I. Razzouk et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dexrazoxane-Associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
Cameron K. Tebbi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
Albert Moghrabi et al.
BLOOD (2007)
Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease
Paul A. Heidenreich et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Protective effects of carvedilol against anthracycline-induced cardiomyopathy
Nihat Kalay et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: Prevalence and risk factors
Kristen A. Neville et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Chronic health conditions in adult survivors of childhood cancer
Kevin C. Oeffinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The prevalence of overweight and obesity in pediatric survivors of cancer
Paul C. Nathan et al.
JOURNAL OF PEDIATRICS (2006)
Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies
KA Wouters et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Preventing organ-specific chemotherapy toxicity
JP Ginsberg et al.
EUROPEAN JOURNAL OF CANCER (2005)
Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment
MS Ewer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pathophysiology of anthracycline- and radiation-associated card iomyopathies: Implications for screening and prevention
MJ Adams et al.
PEDIATRIC BLOOD & CANCER (2005)
Doxorubicin-induced second degree and complete atrioventricular block
S Kilickap et al.
EUROPACE (2005)
Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia
SE Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Body mass index in long-term adult survivors of childhood cancer - A report of the childhood cancer survivor study
LR Meacham et al.
CANCER (2005)
Does anthracycline administration by infusion in children affect late cardiotoxicity?
GA Levitt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia
SE Lipshultz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
QT dispersion correlates with systolic rather than diastolic parameters in patients receiving anthracycline treatment
H Nakamae et al.
INTERNAL MEDICINE (2004)
Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin
CJ Miranda et al.
BLOOD (2003)
Radiation-associated cardiovascular disease: Manifestations and management
MJ Adams et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers
M Gupta et al.
MEDICAL AND PEDIATRIC ONCOLOGY (2003)
Radiation-associated cardiovascular disease
MJ Adams et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2003)
Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer
SE Lipshultz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Predictors of smoking initiation and cessation among childhood cancer survivors: A report from the Childhood Cancer Survivor Study
K Emmons et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography
M Hauser et al.
EUROPEAN JOURNAL OF PEDIATRICS (2001)
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
D Cardinale et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
Share Paper
